# Clinical Outcome of a Patented Pharmaceutical Composition (KT-110) to Treat Alcohol Use Disorder While Avoiding Major Side Effects

> **NCT04108104** · PHASE2 · COMPLETED · sponsor: **Kinnov Therapeutics** · enrollment: 154 (actual)

## Conditions studied

- Alcohol Use Disorder

## Interventions

- **DRUG:** Cyproheptadine
- **DRUG:** Alpress LP

## Key facts

- **NCT ID:** NCT04108104
- **Lead sponsor:** Kinnov Therapeutics
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-11-30
- **Primary completion:** 2021-10-28
- **Final completion:** 2022-01-31
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2024-04-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04108104

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04108104, "Clinical Outcome of a Patented Pharmaceutical Composition (KT-110) to Treat Alcohol Use Disorder While Avoiding Major Side Effects". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT04108104. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*